Honasa Consumer Ltd, the publicly listed parent company of D2C beauty unicorn Mamaearth, has officially announced the acquisition of a 58% majority stake in Mumbai-based nutraceuticals firm Fluence Pharma.
The strategic buyout, executed entirely via secondary share purchases, is based on an enterprise value of ₹135 crore (estimated around $15–$18 million) and marks Mamaearth’s definitive entry into the fast-growing “inside-out” beauty and wellness supplements market.
1. Structuring the Acquisition Timeline
The transaction enables Honasa Consumer to establish an immediate controlling foothold while mapping out a complete absorption of the target company over the medium term:
- The Initial Tranche: Honasa is acquiring the initial 58% majority block, a transaction expected to officially close within the next eight weeks subject to standard closing adjustments.
- The Path to 100%: According to the company’s stock exchange filing, Honasa retains a structured mandate to purchase the remaining 42% equity stake from the founders in two separate tranches over the next five to seven years.
[Secondary Share Purchase] ──► 58% Immediate Control (₹135Cr EV) ──► 2 Tranches Over 5-7 Years ──► 100% Full Ownership
2. Who is Fluence Pharma?
In stark contrast to Honasa’s venture-backed trajectory, Fluence Pharma has grown organically on practitioner trust without relying on external institutional funding.
- The Background: Founded in 2012 by pharmaceutical industry veterans Amit Bhusari and Dr. Rajendra Singh Rajput, the firm develops over-the-counter (OTC) nutritional supplements targeting condition-specific hair and skin health.
- The Flagship Tech: The company is best known in medical circles for its patented Cyclical Nutrition Therapy (CNT) platform—a phased, regimen-driven nutritional model built to systematically treat urban anomalies like hair thinning and hair fall.
- The Clinical Portfolio: Fluence distributes its specialized supplement arrays under highly regarded practitioner brands, including Hair Fact, Skin Fact, and Pro Fact.
- Financial & Distribution Metrics: The company is backed by a robust network of more than 3,000 dermatologists across India. For the fiscal year ended March 2026 (FY26), Fluence reported a revenue of approximately ₹40 crore while maintaining healthy EBITDA margins exceeding 20%. Notably, hair-focused products generate over 70% of its total baseline revenues.
3. The Birth of “Honasa Health”
To seamlessly scale its new nutrition playbook, Honasa Consumer’s board has approved the incorporation of a brand-new, wholly owned subsidiary named Honasa Health Pvt. Ltd.
The Integration Synergy: Honasa Health will serve as the dedicated vehicle to scale a highly differentiated, business-to-consumer (B2C) wellness portfolio. The business model will marry Fluence’s patented clinical science and deep practitioner trust with Mamaearth’s proven mastery in digital-first distribution, high-velocity brand building, and consumer insights.
The newly formed subsidiary will be spearheaded by Dheeraj Nagpal as CEO. Nagpal brings extensive consumer scaling experience to the table, having previously co-founded the nutraceutical brand Zingavita alongside holding past leadership roles at Zomato and American Express.
4. Capitalizing on India’s ₹16,000 Crore “Inside-Out” Trend
The acquisition lands amidst a massive, industry-wide consolidation wave sweeping through India’s ₹16,000 crore beauty and wellness sector, driven by a structural shift in consumer behavior:
| Consolidating Major | Target Entity / Brand | Strategic Category Aim |
| Honasa Consumer (Mamaearth) | Fluence Pharma (58% Stake / ₹135Cr EV) | Science-backed hair/skin nutraceuticals |
| Honasa Consumer (Mamaearth) | Reginald Men (90% Stake / ₹195Cr EV) | Premium Men’s Grooming (Dec 2025) |
| Marico | Cosmix (60% Stake / ₹375Cr Valuation) | Plant-based wellness mixes |
| Hindustan Unilever (HUL) | Oziva (100% Absorption / ₹824Cr) | Clean, plant-based nutrition |
Co-founder and CEO Varun Alagh highlighted that while the last decade of Indian beauty was heavily shaped by topical active ingredients (serums and creams), the next decade will be fundamentally defined by the convergence of science-backed personal care and ingestion-based nutraceuticals. Backed by a strong financial recovery in its flagship Mamaearth brand, Honasa expects its total revenue growth to cross market expectations in the ongoing fiscal year, tracking high-teen percentage expansions.
